AEssential thrombocythemia
First line
Essential thrombocythemia
First line
Hydroxycarbamide is a cytostatic drug that suppresses dividing bone marrow cells and lowers the platelet count. In essential thrombocythemia it is used under the Hydrea ficha técnica (AEMPS), which lists the disease among the myeloproliferative syndromes. The ficha gives a loading dose of 25 to 50 mg/kg a day and a maintenance dose of 10 to 20 mg/kg; the dose is then adjusted to blood counts and continued while platelets and white cells stay controlled. The European LeukemiaNet recommendations (ELN 2018) group patients by age and thrombosis: high risk means age 60 or older or a prior thrombosis. Hydroxycarbamide was tested in RCTs in exactly these patients. In the Cortelazzo trial (NEJM 1995, 114 patients), thrombosis occurred over a median of 27 months in 3.6 percent on hydroxycarbamide and in 24 percent without cytoreduction. In PT-1 (NEJM 2005, 809 patients, all on low-dose aspirin), the composite endpoint of arterial and venous thrombosis, serious bleeding or death from them was reached more often on anagrelide than on hydroxycarbamide (OR 1.57). Anagrelide brought more arterial thrombosis, serious bleeding and transformation to myelofibrosis, but less venous thromboembolism. ELN 2018 recommends hydroxycarbamide or interferon alfa as first-line therapy when cytoreduction is needed, and anagrelide or interferon as second line after hydroxycarbamide fails or is not tolerated. With long-term use the ficha describes leg ulcers in about 9 percent of patients and skin cancer, so the skin is checked regularly.
Sources
- AEMPS: Ficha técnica de Hydrea 500 mg cápsulas duras (nº registro 61633) (2025)
- New England Journal of Medicine: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis (1995)
- MRC Primary Thrombocythemia 1: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia (2005)
- European LeukemiaNet: Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet (2018)
ICD-10: D47.3